Epithelial transport and gut barrier function in colitis

Current Opinion in Gastroenterology

Volumn 19, Issue 6, 2003, Pages 578-582

  McCole, Declan F ^a   Barrett, Kim E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Butyrate; Mucins; Multidrug resistance proteins; Na+ K+ ATPase; NOD 2

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DEFENSIN; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTESTINAL TREFOIL FACTOR; KERATINOCYTE GROWTH FACTOR; MUCIN; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; REPIFERMIN; SODIUM PROTON EXCHANGE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

COLITIS; DIARRHEA; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE TRANSPORT; ENTERITIS; HUMAN; INTESTINE MUCOSA; ION TRANSPORT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; TRANSPORT KINETICS; WATER TRANSPORT;

EID: 0142247096     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200311000-00011     Document Type: Review

References (36)

1. Lohi H, Maketa S, Pulkkinen K, et al.: Upregulation of CFTR expression but not SLC26A3 and SLC9A3 in ulcerative colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283:G567-G575.
2. +-ATPaSe activity.
3. Burgel N, Bojarski C, Mankertz J, et al.: Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002, 123:433-443.
4. Kroesen AJ, Stockmann M, Ransco C, et al.: Impairment of epithelial transport but not of barrier function in idiopathic pouchitis after ulcerative colitis. Gut 2002, 50:821-826.
5. + absorption via ENaC, and not a barrier defect, was responsible for diarrhea in this model.
6. Claud EC, Li D, Xiao Y, et al.: Platelet-activating factor regulates chloride transport in colonic epithelial cell monolayers. Pediatr Res 2002, 52:155-162.
7. Sanchez AL, Langdon CM, Akhtar M, et al.: Adenoviral transfer of the murine oncostatin M gene suppresses dextran-sodium sulfate-induced colitis. J Interferon Cytokine Res 2003, 23:193-201.
8. Willemsen LEM, Schreurs CCHM, Kroes H, et al.: A coculture model mimicking the intestinal mucosa reveals a regulatory role for myofibroblasts in immune-mediated barrier disruption. Dig Dis Sci 2002, 47:2316-2324.
9. Chen M, O'Toole EA, Sanghavi J, et al.: The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with Crohn's disease have autoantibodies to type VII collagen. J Invest Dermatol 2002, 118:1059-1064.
10. Poussier P, Ning T, Banerjee D, Julius M: A unique subset of self-specific intraintestinal T cells maintains gut integrity. J Exp Med 2002, 195:1491-1497.
11. McCarn K, Yursik B, Halim S, Roche JK: Peri-epithelial origin of prostanoids in the human colon. J Cell Physiol 2003, 194:176-185.
12. Kinoshita M, Suzuki Y, Saito Y: Butyrate reduces colonic paracellular permeability by enhancing PPAR-gamma activation. Biochem Biophys Res Commun 2002, 293:827-831.
13. Esworthy RS, Binder SW, Doroshow JH, Chu FF: Microflora trigger colitis in mice deficient in selenium-dependent glutathione peroxidase and induce Gpx2 gene expression. Biol Chem 2003, 384:597-607.
14. Cenac N, Coelho AM, Nguyen C, et al.: Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 2002, 161:1903-1915. PAR-2, a GPCR for trypsin, levels of which are elevated in IBD, is highly expressed in the intestine. Colonic administration of PAR-2 agonists to mice increased PAR-2 expression, caused inflammation, increased colonic permeability, and induced bacterial translocation, suggesting that PAR-2 may be involved in IBD pathogenesis.
15. Playford RJ, Hanby AM, Patel K, Calam J: Influence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon. Am J Pathol 1995, 146:310-316.
16. Mizoguchi E, Xavier RJ, Reinecker HC, et al.: Colonic epithelial functional phenotype varies with type and phase of experimental colitis. Gastroenterology 2003, 125:148-161. Using DNA microarray analysis and immunohistochemistry, the authors show that isolated murine colonic epithelial cells express reduced levels of detoxification molecules involved in inhibiting inflammation in chronic, but not acute, colitis. In contrast, molecules with antiinflammatory functions are upregulated during both acute and chronic colitis.
17. Vetuschi A, Latella G, Sferra R, et al.: Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 2002, 47:1447-1457.
18. Steinkamp M, Geerling I, Seufferlein T, et al.: Glial-derived neurotrophic factor regulates apoptosis in colonic epithelial cells. Gastroenterology 2003, 124:1748-1757.
19. Beck PL, Rosenberg IM, Xavier RJ, et al.: Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am J Pathol 2003, 162:597-608. The authors show that epithelial overexpression of a dominant negative TGF-β receptor (RII) blocks TGF-β-stimulated healing in wounded epithelial monolayers and increases susceptibility to DSS colitis in transgenic mice.
20. Renes IB, Verburg M, van Nispen DJ, et al.: Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. Int J Colorectal Dis 2002, 17:317-326. The authors show that acute DSS treatment of mice increases epithelial apoptosis and decreases proliferation and enterocyte functions. Increases in goblet cell numbers and expression of the mucin MUC2 and intestinal trefoil factor 3 indicate a role in barrier repair.
21. Mattar AF, Teitelbaum DH, Drongowski RA, et al.: Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 2002, 18:586-590.
22. Wehkamp J, Schwind B, Herrlinger KR, et al.: Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci 2002, 47:1349-1355.
23. Wehkamp J, Fellermann K, Herrlinger KR, et al.: Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonie mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002, 14:745-752.
24. Rosenstiel P, Fantini M, Brautigam K, et al.: TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003, 124:1001-1009. TNF-α(/IFN-γ) treatment upregulates NOD2 gene expression in an NF-κB-dependent manner in intestinal epithelial cells. Cells overexpressing NOD2 show an increased responsiveness to lipopolysacaride as measured by IL-8 production.
25. Hisamatsu T, Suzuki M, Reinecker HC, et al.: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003, 124:993-1000. The authors demonstrate CARD15/NOD2 expression in intestinal epithelial cell lines and in primary intestinal epithelial cells. Stable transfection of CARD15/NOD2 in Caco-2 cells decreased S. typhimurium survival, while expression of the NOD2 mutation associated with Crohn's disease was of no benefit.
26. Schwab M, Schaeffeler E, Marx C, et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003, 124:26-33. The finding that the mdr1a (P-glycoprotein-encoding gene) knockout mouse develops colitis similar to UC prompted this study. Allele frequencies and genotype distributions of the C3435T single nucleotide polymorphism indicate a higher frequency in UC patients than controls, indicating that an impairment in P-glycoprotein function may increase susceptibility to UC.
27. Ten Hove T, Drillenburg P, Wijnholds J, et al.: Differential susceptibility of multidrug resistance protein-1 deficient mice to DSS and TNBS-induced colitis. Dig Dis Sci 2002, 47:2056-2063.
28. 51Cr-EDTA, in Crohn's patients. This study suggests that inhibiting TNF-mediated inflammation directly results in restoration of barrier integrity.
29. 2 inhibitor. Am J Physiol Gastrointest Liver Physiol 2003, 285:G586-G592.
30. Popoff I, Jijon H, Monia B, et al.: Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J Pharmacol Exp Ther 2002, 303:1145-1154. Following studies showing attenuation of inflammation by pharmacological inhibition of poly (ADP-ribose) polymerase 2, an antisense oligonucleotide inhibitor of poly (ADP-ribose) polymerase 2, administered to IL-10 deficient mice with spontaneous colitis, normalized colonic epithelial barrier and transport function, reduced proinflammatory cytokine secretion, and attenuated colitis.
31. Sasaki M, Bharwani S, Jordan P, et al.: The 3-hydroxy-3-methylglutaryl- CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 2003, 305:78-85.
32. Sasaki S, Yoneyama H, Suzuki K, et al.: Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 2002, 32:3197-3205.
33. Zolotarevsky Y, Hecht G, Koutsouris A, et al.: A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002, 123:163-172. A novel peptide inhibitor of myosin light chain kinase prevents enteropathogenic E. coli-induced decreases in transepithelial resistance across intestinal epithelial cell monolayers and reverses decreases in resistance induced by TNF-α and IFN-γ. The authors suggest this agent may be of therapeutic value in restoring barrier function in intestinal diseases.
34. Greenwood-Van Meerveld B, Venkova K, et al.: Efficacy of repifermin (keratinocyte growth factor-2) against abnormalities in gastrointestinal mucosal transport in a murine model of colitis. J Pharm Pharmacol 2003, 55:67-75.
35. Sandborn WJ, Sands BE, Wolf DC, et al.: Repifermin (keratinocyte growth factor 2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003, 17:1355-1364.
36. Venkatraman A, Ramakrishna BS, Shaji RV, et al.: Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2003, 285:G177-G184.